ALKSALKSHealthcare · Drug Manufacturers - Specialty & Generic

ALKS Stock Forecast: Alkermes Plc Price Predictions for 2026-2027

Last close, 18 Nov 2026
$47
+3.08% on the day

The 20 Wall Street analysts covering Alkermes Plc hold a median 12-month price target of $60 — +28.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 17 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$7.6B
Ticker Nerd rank
70/ 100
Median analyst target
$60
Analysts covering
20
Revenue$392.9M+28.2% y/y
Operating income−$48.3M
Net income−$66.5M
Free cash flow−$169.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.2%
1M
+13.7%
YTD
+67.4%
1Y
+60.1%
From 52W high
−15.2%
From 52W low
+72.2%
$27
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALKS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alkermes Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
70/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
97
Momentum
89
Quality
80
Revisions
63
Accruals
44
Growth
43
Issuance
18
Size
18

Volatility (98): The share price has been relatively steady.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALKS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALKS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80$90Jan 26Apr 26Jul 26Oct 26ALKSHigh $83Median $60Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
15 Buy4 Hold1 Sell
Low $38Median $60High $83

The green dot is the last close — the median target sits +28.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Nov 2026HC Wainwright & Co.MaintainsNeutral$43 → $50
4 Nov 2026RBC CapitalMaintainsOutperform$56 → $57
4 Nov 2026Wells FargoMaintainsOverweight$65 → $68
24 Sept 2026Goldman SachsReinstatesNeutral$50
22 Sept 2026BairdMaintainsOutperform—
22 Sept 2026BairdMaintainsOutperform$58 → $61
22 Sept 2026RBC CapitalReiteratesOutperform—
22 Sept 2026RBC CapitalReiteratesOutperform$56
21 Sept 2026NeedhamReiteratesBuy$62
21 Sept 2026NeedhamReiteratesBuy—
29 July 2026BairdMaintainsOutperform—
29 July 2026BairdMaintainsOutperform$48 → $58
29 July 2026JP MorganMaintainsNeutral$60 → $61
29 July 2026JP MorganMaintainsNeutral—
28 July 2026Piper SandlerReiteratesOverweight—
28 July 2026Piper SandlerReiteratesOverweight$43 → $65
20 July 2026StifelReiteratesBuy$45 → $63
20 July 2026StifelReiteratesBuy—
13 July 2026JP MorganReinstatesNeutral$60
13 July 2026NeedhamMaintainsBuy$61 → $62

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALKS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALKS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Alkermes Plc returned +60.1% against +12.2% for the S&P 500, dividends included.

ALKS vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26ALKSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALKS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+21.6%
Analysts raising
1
Analysts cutting
1
Fundamentals

Alkermes Plc (ALKS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
123.2×

Cheaper than 5% of US stocks

Price / sales
4.4×

Cheaper than 25% of US stocks

Price / book
4.1×

Cheaper than 22% of US stocks

EV / EBITDA
30.0×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
21.8%

Higher than 71% of US stocks

Earnings growth (YoY)
−80.3%

Higher than 5% of US stocks

Gross margin
84.3%

Higher than 93% of US stocks

Operating margin
11.5%

Higher than 68% of US stocks

Net margin
−0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−0.0%

Higher than 44% of US stocks

Return on assets
3.7%

Higher than 69% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alkermes Plc (ALKS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alkermes Plc has a market value of $7.6B and an enterprise value of $8.5B.

  • Revenue in the twelve months to 31 Mar 2026: $1.6B. The latest quarter grew 21.8% year on year.

  • Net income over the same four quarters: $152.7M, a 9.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.90.

  • Free cash flow in the twelve months to 31 Mar 2026: $221.8M, after $35.0M of capital spending.

  • Alkermes Plc spent $27.7M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 168.0M.

  • Trailing P/E: 123.2×; forward P/E: 33.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alkermes Plc employs 2,050 people — $762K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ALKS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALKSAlkermes Plc$7.6B70
AMRXAmneal Pharmaceuticals, Inc.$7.4B83
KNSAKiniksa Pharmaceuticals International Plc$7.3B98
LNTHLantheus Holdings, Inc.$6.6B98
SUPN.1Supernus, Inc.$6.0B89
LQDALiquidia Corp.$5.1B97
ELANElanco Animal Health, Inc.$12.9B97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alkermes Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALKS news & analysis

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

MarketBeat · 16 Nov 2026positive

Alkermes CEO Blair Jackson said the company expects clinical readouts across its orexin programs in sleep disorders, ADHD and fatigue over the next 12 months. The headline also notes a LUMRYZ filing is ahead.

Why it matters — The anticipated readouts and filing are upcoming developments for ALKS watchers to follow.

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

Business Wire · 5 Nov 2026positive

Alkermes plans to present research from its psychiatry and sleep medicine portfolios at the NEI Fall Congress, scheduled for Nov. 5–8, 2026, in Colorado Springs. Presentations will include data related to LYBALVI, ARISTADA, LUMRYZ and investigational alixorexton.

Why it matters — The presentations will provide updates on research across several of Alkermes’ psychiatry and sleep medicine programs.

Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

Alkermes held its Q3 2026 earnings call on November 3, 2026. The excerpt lists company representatives and participating analysts but provides no discussion of results or business updates.

Why it matters — ALKS watchers can note the call occurred, though the supplied text contains no substantive information about the company’s performance or outlook.

Alkermes to Present at Upcoming Investor Conferences

Business Wire · 3 Nov 2026neutral

Alkermes said management will participate in the Stifel 2026 Healthcare Conference on Nov. 10 and the Jefferies Global Healthcare Conference in London on Nov. 18, with fireside chats scheduled at both events. Live webcasts will be available through the company’s Investors tab and archived.

Why it matters — The appearances provide ALKS watchers with scheduled opportunities to hear from management and follow its conference remarks.

What Alkermes (ALKS) Said on Its Q3 Earnings Call

MarketBeat · 3 Nov 2026positive

Alkermes reported 31% year-over-year growth in proprietary product sales in its third-quarter 2026 results. Management also highlighted continued investment in its orexin development portfolio across sleep, neuropsychiatric and neurological disorders.

Why it matters — ALKS watchers may note the reported sales growth alongside ongoing development investment in the orexin portfolio.

FAQ

Frequently asked questions about ALKS stock

What is the ALKS stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Alkermes Plc have a median 12-month price target of $60, with estimates ranging from $38 to $83. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALKS stock a buy right now?

Of the 20 analysts covering Alkermes Plc, 15 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alkermes Plc 70 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALKS?

As at 17 Nov 2026, Alkermes Plc ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will ALKS stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +28.1% from the last close, and Ticker Nerd's factor model ranks Alkermes Plc 70 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALKS stock forecast for 2030?

No analyst covering Alkermes Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALKS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $83 over the next 12 months.

How has ALKS stock performed over the past year?

Alkermes Plc returned +60.1% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alkermes Plc do?

Alkermes plc is a global biopharmaceutical company focused on developing and commercializing medicines for complex neurological and psychiatric conditions. Its current portfolio addresses opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder, and narcolepsy, serving patients and healthcare providers primarily in the United States and international markets.

What is the latest news on ALKS?

The most recent item we track (MarketBeat, 16 Nov 2026): "Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead". Alkermes CEO Blair Jackson said the company expects clinical readouts across its orexin programs in sleep disorders, ADHD and fatigue over the next 12 months. The headline also notes a LUMRYZ filing is ahead.

Company

About Alkermes Plc.

Alkermes plc is a global biopharmaceutical company focused on developing and commercializing medicines for complex neurological and psychiatric conditions. Its current portfolio addresses opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder, and narcolepsy, serving patients and healthcare providers primarily in the United States and international markets. The company combines proprietary drug development with specialized delivery technologies designed to support treatment continuity and clinical use. Its products include long-acting injectable therapies and oral medicines, giving healthcare professionals options across different treatment settings and patient needs. Alkermes plc also maintains clinical and preclinical programs centered on neurological disorders, reinforcing its role in neuroscience-focused pharmaceutical research. Through its commercial medicines, research capabilities, and presence in behavioral health markets, the company contributes to the development and availability of treatments for conditions that can require sustained management and coordinated care. Headquartered in Ireland, Alkermes plc operates across research, manufacturing, regulatory, and commercial functions within the biopharmaceutical industry.

CEO Mr. Blair C. Jackson · 2,050 employees · Ireland · https://www.alkermes.com